MX2023003258A - Tratamiento de enfermedades mediadas por nf-kb. - Google Patents

Tratamiento de enfermedades mediadas por nf-kb.

Info

Publication number
MX2023003258A
MX2023003258A MX2023003258A MX2023003258A MX2023003258A MX 2023003258 A MX2023003258 A MX 2023003258A MX 2023003258 A MX2023003258 A MX 2023003258A MX 2023003258 A MX2023003258 A MX 2023003258A MX 2023003258 A MX2023003258 A MX 2023003258A
Authority
MX
Mexico
Prior art keywords
îob
treatment
mediated disease
human patient
vamorolone
Prior art date
Application number
MX2023003258A
Other languages
English (en)
Spanish (es)
Inventor
Jesse Damsker
Eric Hoffman
Original Assignee
Reveragen Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reveragen Biopharma Inc filed Critical Reveragen Biopharma Inc
Publication of MX2023003258A publication Critical patent/MX2023003258A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023003258A 2020-09-21 2021-09-21 Tratamiento de enfermedades mediadas por nf-kb. MX2023003258A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063081073P 2020-09-21 2020-09-21
US202163195473P 2021-06-01 2021-06-01
US202163214908P 2021-06-25 2021-06-25
PCT/US2021/051274 WO2022061287A1 (en) 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE

Publications (1)

Publication Number Publication Date
MX2023003258A true MX2023003258A (es) 2023-05-08

Family

ID=80776432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003258A MX2023003258A (es) 2020-09-21 2021-09-21 Tratamiento de enfermedades mediadas por nf-kb.

Country Status (9)

Country Link
US (2) US20220184098A1 (cg-RX-API-DMAC10.html)
EP (1) EP4213855A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023543439A (cg-RX-API-DMAC10.html)
KR (1) KR20230092905A (cg-RX-API-DMAC10.html)
AU (1) AU2021343534A1 (cg-RX-API-DMAC10.html)
CA (1) CA3170698A1 (cg-RX-API-DMAC10.html)
IL (1) IL301500A (cg-RX-API-DMAC10.html)
MX (1) MX2023003258A (cg-RX-API-DMAC10.html)
WO (1) WO2022061287A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436583A4 (en) * 2021-11-22 2025-04-02 ReveraGen BioPharma, Inc. TREATMENT OF NF-kB-MEDIATED DISEASE
WO2025199347A1 (en) * 2024-03-21 2025-09-25 Reveragen Biopharma, Inc. Treatment of glomerulonephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279325B2 (en) * 2005-08-18 2013-06-27 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP2785351A4 (en) * 2011-11-29 2015-05-27 Reveragen Biopharma Inc NONTHORMONAL STEROID MODULATORS OF NF-KB FOR THE TREATMENT OF DISEASES
WO2014205045A1 (en) * 2013-06-18 2014-12-24 Downes, Michael Methods of treating muscular dystrophy
WO2017044491A1 (en) * 2015-09-08 2017-03-16 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
US11382922B2 (en) * 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Also Published As

Publication number Publication date
AU2021343534A1 (en) 2023-05-11
US20220184098A1 (en) 2022-06-16
EP4213855A4 (en) 2024-10-23
EP4213855A1 (en) 2023-07-26
US20240139210A1 (en) 2024-05-02
IL301500A (en) 2023-05-01
WO2022061287A1 (en) 2022-03-24
CA3170698A1 (en) 2022-03-24
KR20230092905A (ko) 2023-06-26
JP2023543439A (ja) 2023-10-16

Similar Documents

Publication Publication Date Title
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
NZ591362A (en) Multiple-variable dose regimen for treating tnfa-related disorders
MX2024008350A (es) Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
MX2023001140A (es) Uso del dexpramipexol para el tratamiento de asma moderado a grave.
MX2024011142A (es) Tratamiento de neurofibromas cutaneos con mirdametinib.
SE0400184D0 (sv) New therapeutical use
MX2022001287A (es) Composiciones y metodos de uso de celulas madre multipotentes para reducir la enfermedad y mejorar el bienestar.
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
MX2026002937A (es) Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos
CA2899234C (en) Method of treating fibrosis in skeletal muscle tissue
IL318374A (en) Methods of administering nalbuphine
GB0405381D0 (en) A method and means for treating heart failure
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
MX2022011030A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla.
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
WO2008088987B1 (en) Treatment of pain with naloxone
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
MX2024005374A (es) Metodos para tratar la enfermedad de celulas falciformes con voxelotor.
Akshaya et al. Effect of Dry Needling on Patients with Lumbar Radiculopathy in Reducing Pain and Increasing Range of Motion Compared to Interferential Therapy.
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
MX2024002602A (es) Métodos para prevenir y tratar el dolor y síntomas asociados.